Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-Mirc415 PET/CT for PD-L2 Imaging in Solid Tumors
NCT05803746Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-Mirc415 in lung cancer, colorectal cancer (CRC) and solid tumor, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major Pathologic Response. Status: unknown.
02
Drugs
68Ga-Mirc415
03
Conditions
lung cancercolorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05803746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803746.